

Diabetic Kidney Disease Strategy Conference: Implementing New Diabetic Kidney Disease Treatments - Time for Nephrologists to Act

Capital Hilton, Washington, DC January 14, 2020

Working Together to Address the Urgent and Unmet Needs in the Diagnosis and Treatment of People with Diabetic Kidney Disease

Agenda

7:30 AM Plated Breakfast

8:00 AM Introductory Remarks

Welcome and DKD-C introduction, patient perspective, description of optimal care for DKD

Susan Quaggin, MD Northwestern University

Patrick Gee, PhD Patient Advocate
Frank (Chip) Brosius, MD University of Arizona

8:30 AM New Therapies for Diabetic Kidney Disease: SGLT2 Inhibitors from CVOTs to Dedicated

CKD Trials

Overview of the success of SGLT2i trials and how to use these agents

David Cherney, MD University of Toronto

9:00 AM New Therapies for Diabetic Kidney Disease: GLP-1 Receptor Agonists and Non-Glycemic

Agents

Opportunities for other agents

Katherine Tuttle, MD University of Washington

9:30 AM State of DKD Care Implementation

Best practices

Adeera Levin, MD University of British Columbia

10:00 AM Break

10:15 AM Panel Discussion

AAKH: Preventing Kidney Failure through Better Diagnosis, Treatment, and Incentives

for Preventative Care

Provide an overview of AAKH with a focus on preventative care and its application to DKD

Moderator: Susan Quaggin, MD Northwestern University





11:15 AM Breakout Sessions - Perspectives on the Implementation of New Therapies for DKD

Review objectives and logistics for the breakout sessions

David Cherney, MD University of Toronto

1. Nephrologists

Group 1 Moderator - Alan Kliger, MD Yale New Haven Health System

2. Nephrologists

Group 2 Moderator - Adeera Levin, MD University of British Columbia

3. Pharmaceutical

Moderator - Raymond Harris, MD Vanderbilt University Medical Center

4. Healthcare Delivery

Moderator – Chip Brosius, MD University of Arizona

5. Kidney Disease Patients

Moderator - Patrick Gee, PhD Patient Advocate

12:30 PM Plated Lunch

1:00 PM Breakout Session Reports on the Implementation of New Therapies for DKD

1:00 PM Kidney Disease Patients

1:10 PM **Nephrologists**

Group 1 Group 2

1:30 PM **Pharmaceutical**

1:40 PM **Healthcare Delivery**

1:50 PM Break

2:10 PM Next Steps: A Call to Action

Discuss the recommendations from each breakout group to create a platform for a DKD

implementation strategy

Sue Quaggin, MD and the DKD-C Task Force

3:00 PM Adjourn

